VIVUS, Inc. (NASDAQ:VVUS)

CAPS Rating: 2 out of 5

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

Recs

0
Player Avatar JorgeAura (< 20) Submitted: 12/6/2012 7:37:42 PM : Underperform Start Price: $10.99 VVUS Score: -10.96

This company have a good future. But, at this moment overvalued. Vivus have zero revenues.

Featured Broker Partners


Advertisement